Pedro Miguel Lacal

Summary

Affiliation: Istituto Dermopatico dell'Immacolata
Country: Italy

Publications

  1. ncbi Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor
    P M Lacal
    Laboratory of Clinical Pharmacology, Istituto Dermopatico dell Immacolata, IRCCS, Rome, Italy
    J Invest Dermatol 115:1000-7. 2000
  2. ncbi Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide
    Pedro M Lacal
    Laboratory of Molecular Oncology, Istituto Dermopatico dell Immacolata IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy
    Eur J Cancer 44:1914-21. 2008
  3. ncbi An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells
    Pedro Miguel Lacal
    Laboratory of Molecular Oncology, Istituto Dermopatico dell Immacolata IRCCS, I 00167 Rome, Italy
    Int J Oncol 27:1625-32. 2005
  4. ncbi A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through alpha5beta1 integrin
    Simonetta Soro
    Department of Biochemical Sciences A Rossi Fanelli, University La Sapienza, Rome, Italy
    Blood 111:3479-88. 2008
  5. ncbi Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells
    Pedro Miguel Lacal
    Laboratory of Molecular Oncology, Istituto Dermopatico dell Immacolata, 00167 Rome, Italy
    Int J Oncol 34:861-72. 2009
  6. ncbi Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor
    Marcella Marcellini
    Laboratory of Experimental Angiogenesis, Sigma Tau, Rome, Italy
    Am J Pathol 169:643-54. 2006
  7. ncbi Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis
    Lucio Tentori
    Department of Neuroscience, University of Rome Tor Vergata, Via Montpellier 1, Rome, Italy
    Eur J Cancer 43:2124-33. 2007
  8. ncbi Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential
    Francesca Cianfarani
    Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Via dei Monti di Creta, 104, 00167 Rome, Italy
    Am J Pathol 169:1167-82. 2006
  9. ncbi Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB
    Lauretta Levati
    Laboratory of Molecular Oncology, Istituto Dermopatico dell Immacolata IRCCS, Rome, Italy
    Int J Oncol 38:241-7. 2011
  10. ncbi Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin
    Angela Orecchia
    Molecular and Cell Biology Laboratory, IDI IRCCS, Via Monti di Creta 104, 00167 Rome, Italy
    J Cell Sci 116:3479-89. 2003

Collaborators

Detail Information

Publications14

  1. ncbi Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor
    P M Lacal
    Laboratory of Clinical Pharmacology, Istituto Dermopatico dell Immacolata, IRCCS, Rome, Italy
    J Invest Dermatol 115:1000-7. 2000
    ..J Invest Dermatol 115:1000-1007 2000..
  2. ncbi Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide
    Pedro M Lacal
    Laboratory of Molecular Oncology, Istituto Dermopatico dell Immacolata IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy
    Eur J Cancer 44:1914-21. 2008
    ..Altogether, these data demonstrate that peptide B3 might be a useful tool for the specific inhibition of VEGFR-1 function and might represent a basis for the development of new anti-angiogenic compounds...
  3. ncbi An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells
    Pedro Miguel Lacal
    Laboratory of Molecular Oncology, Istituto Dermopatico dell Immacolata IRCCS, I 00167 Rome, Italy
    Int J Oncol 27:1625-32. 2005
    ....
  4. ncbi A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through alpha5beta1 integrin
    Simonetta Soro
    Department of Biochemical Sciences A Rossi Fanelli, University La Sapienza, Rome, Italy
    Blood 111:3479-88. 2008
    ..Alanine scanning mutagenesis of the peptide defined which residues were responsible for its biologic activity and integrin binding...
  5. ncbi Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells
    Pedro Miguel Lacal
    Laboratory of Molecular Oncology, Istituto Dermopatico dell Immacolata, 00167 Rome, Italy
    Int J Oncol 34:861-72. 2009
    ..In conclusion, these results strongly suggest that PARP activity is capable of modulating molecules required for endothelial cell migration, adhesion, proliferation or differentiation during the angiogenic process...
  6. ncbi Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor
    Marcella Marcellini
    Laboratory of Experimental Angiogenesis, Sigma Tau, Rome, Italy
    Am J Pathol 169:643-54. 2006
    ..These findings indicate that PlGF, in addition to enhancing tumor angiogenesis and favoring tumor growth, may directly influence melanoma dissemination...
  7. ncbi Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis
    Lucio Tentori
    Department of Neuroscience, University of Rome Tor Vergata, Via Montpellier 1, Rome, Italy
    Eur J Cancer 43:2124-33. 2007
    ..These results provide evidence for targeting PARP for anti-angiogenesis, adding novel therapeutic implications to the use of PARP inhibitors in cancer treatment...
  8. ncbi Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential
    Francesca Cianfarani
    Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Via dei Monti di Creta, 104, 00167 Rome, Italy
    Am J Pathol 169:1167-82. 2006
    ....
  9. ncbi Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB
    Lauretta Levati
    Laboratory of Molecular Oncology, Istituto Dermopatico dell Immacolata IRCCS, Rome, Italy
    Int J Oncol 38:241-7. 2011
    ..In conclusion, our data strongly suggest that PlGF plays a role in melanoma cell resistance to TMZ through a pathway that involves NF-κB activation...
  10. ncbi Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin
    Angela Orecchia
    Molecular and Cell Biology Laboratory, IDI IRCCS, Via Monti di Creta 104, 00167 Rome, Italy
    J Cell Sci 116:3479-89. 2003
    ....
  11. ncbi Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs
    Lucio Tentori
    Department of Neuroscience, University of Rome Tor Vergata, I-00133 Rome, Italy
    Int J Oncol 27:525-35. 2005
    ..In conclusion, the immortalized human endothelial line HUV-ST represents a suitable model for studying the efficacy of anti-neovascular therapy, mimicking proliferating neovascular endothelial cells associated to the tumor mass...
  12. ncbi A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system
    Ester Alvino
    Institute of Neurobiology and Molecular Medicine, Tor Vergata Research Area, National Research Council, I-00133 Rome, Italy
    Int J Oncol 29:785-97. 2006
    ..Exposure to TMZ+BG favors the development of MGMT-independent mechanisms of TMZ resistance...
  13. ncbi Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide
    Lucio Tentori
    Department of Neuroscience, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Eur J Cancer 41:2948-57. 2005
    ..In conclusion, PARG inhibition represents an alternative strategy to enhance TMZ efficacy against melanoma in peripheral as well as at CNS site...
  14. ncbi The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma
    Lucio Tentori
    Department of Neuroscience, University of Rome Tor Vergata, 00133 Rome, Italy
    Oncol Rep 19:1039-43. 2008
    ..In conclusion, this study proposes the use of cilengitide in combination with TMZ for the treatment of metastatic melanoma, thereby opening novel perspectives for the use of integrin inhibitors to enhance the efficacy of chemotherapy...